ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Withdrawn before enrolling · Phase 2

Conditions studied: Idiopathic Polypoidal Choroidal Vasculopathy

In brief

To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy

Key facts

Study ID

NCT03374670

Run by

Ophthotech Corporation

People needed

0

Starts

2018-11-01

Expected to finish

2019-12-01

Last updated by the study team

2024-02-21

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of IPCV
• Patients must have had 3 sequential Eylea injections within the previous 4 months

You may not qualify if…

• Intravitreal treatment in the study eye prior to screening, regardless of indication, except 3 prior injections of Eylea
• History or evidence of severe cardiac disease
• Any major surgical procedure within one month of trial entry
• Subjects with a clinically significant laboratory value
• Any treatment with an investigational agent in the past 60 days for any condition
• Women who are pregnant or nursing
• Known serious allergies to the fluorescein dye, ICG dye, iodine, povidone iodine, or to the components or formulation of either Zimura or Eylea

Where it is running

• Retina Consultants of Hawaii — ‘Aiea, Hawaii, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.